Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 6/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ROS1 | P08922 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584636 | 1.00 | ADRB1 (0.54) | ADRB1ADRB3OPRM1OPRD1ADRB2 | |
| SCHEMBL27668001 | 0.88 | ADRB3 (0.55) | ADRB1ADRB3ADRB2KCNA5 | |
| SCHEMBL4584528 | 0.88 | ADRB3 (0.55) | ADRB1ADRB3ADRB2KCNA5 | |
| SCHEMBL4584521 | 0.88 | ADRB3 (0.55) | ADRB1ADRB3ADRB2KCNA5 | |
| SCHEMBL8559634 | 0.88 | ADRB3 (0.54) | ADRB1ADRB3ADRB2EPHX2GAA | |
| SCHEMBL8560298 | 0.83 | ALDH1A1 (0.61) | ADRB1ADRB3OPRM1OPRD1EPHX2 | |
| SCHEMBL8560709 | 0.83 | ALDH1A1 (0.61) | ADRB1ADRB3OPRM1OPRD1EPHX2 | |
| SCHEMBL26177168 | 0.82 | ADRB3 (0.52) | ADRB1ADRB3ADRB2EPHX2 | |
| SCHEMBL5703832 | 0.80 | ADRB3 (0.52) | ADRB1ADRB3ADRB2LMNA | |
| SCHEMBL26177231 | 0.79 | ADRB3 (0.46) | ADRB1ADRB3ADRB2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100582088-C | Aminoalcohol derivatives | ASTELLAS PHARMA INC | 2010-01-20 | — | — | CN | disclosed |
| US-7417060-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2008-08-26 | — | — | US | disclosed |
| CN-1906154-A | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 2007-01-31 | — | — | CN | disclosed |
| EP-1697301-A2 | AMINOALCOHOL DERIVATIVES | Astellas Pharma Inc. (JP) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061433-A2 | AMINOALCOHOL DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | WO | disclosed |
| US-20050137236-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137236-A1 | Aminoalcohol derivatives | GPR39, PRMT9, CHRM2 | ADRB1 70/4885ADRB3 86/4885OPRM1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.